Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform

What You Should Know: 

– Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S. 

– The collaboration aims to improve patient care and streamline diabetes management for endocrinology practices and their patients.

Enhance Diabetes Management and Improve Patient Outcomes

The integration allows SweetSpot to seamlessly access and analyze data from Eversense 365, the world’s first and only one-year CGM system. This enables SweetSpot’s virtual team of Certified Diabetes Care and Education Specialists (CDCES) to conduct regular CGM data reviews, coordinate with providers, and provide personalized support to patients between their scheduled appointments.

Eversense 365 is the only implantable CGM system available, offering patients a unique and convenient way to monitor their glucose levels continuously for a full year. This eliminates the need for frequent sensor replacements and provides patients with greater peace of mind. Key benefits of the integration include:

• Enhanced Patient Care: Regular CGM data reviews and personalized support from CDCES can lead to more timely treatment adjustments and improved glycemic control.
• Improved Patient Engagement: Increased communication and support from the care team can help patients feel more connected and engaged in their diabetes management.
• Streamlined Workflow: The integration enables seamless data sharing between Eversense 365 and SweetSpot, streamlining workflows for both patients and providers.
• Increased Efficiency: Automated capture of reimbursable care events can improve operational efficiency for endocrinology practices.

“SweetSpot removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care. Our dedicated team is passionate about transforming how diabetes is managed – and making sure that no opportunities are missed to use the rich data from CGMs for improved care. This integration with Eversense reinforces SweetSpot’s commitment to seamless diabetes management, driving better patient outcomes and practice growth for our partners by integrating more CGM options, such as the only implantable CGM on the market,” saidDr Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot.